Literature DB >> 9679884

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.

H Wessells1, K Fuciarelli, J Hansen, M E Hadley, V J Hruby, R Dorr, N Levine.   

Abstract

PURPOSE: We evaluated the erectogenic properties of a new cyclic alpha-melanocyte-stimulating hormone analogue, Melanotan-II, to treat men with psychogenic erectile dysfunction.
MATERIALS AND METHODS: Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring. The presence, duration and rigidity of erections were recorded during a 6-hour period.
RESULTS: In 8 of 10 men treated with Melanotan-II clinically apparent erections developed. Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p=0.0045). Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment.
CONCLUSIONS: Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679884

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  44 in total

1.  Approaches to the rational design of selective melanocortin receptor antagonists.

Authors:  Victor J Hruby; Minying Cai; Joel Nyberg; Dhanasekaran Muthu
Journal:  Expert Opin Drug Discov       Date:  2011-03-24       Impact factor: 6.098

Review 2.  Melanocortinergic control of penile erection.

Authors:  H Wessells; J E Blevins; T W Vanderah
Journal:  Peptides       Date:  2005-10       Impact factor: 3.750

3.  Effects of macrocycle size and rigidity on melanocortin receptor-1 and -5 selectivity in cyclic lactam alpha-melanocyte-stimulating hormone analogs.

Authors:  Alexander V Mayorov; So-Yeop Han; Minying Cai; Matthew R Hammer; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

4.  Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.

Authors:  James P Cain; Alexander V Mayorov; Minying Cai; Hui Wang; Bahar Tan; Kevin Chandler; YeonSun Lee; Ravil R Petrov; Dev Trivedi; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2006-08-22       Impact factor: 2.823

5.  Cell signaling and trafficking of human melanocortin receptors in real time using two-photon fluorescence and confocal laser microscopy: differentiation of agonists and antagonists.

Authors:  Minying Cai; Eva V Varga; Magda Stankova; Alexander Mayorov; Joseph W Perry; Henry I Yamamura; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-10       Impact factor: 2.817

6.  Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists.

Authors:  Minying Cai; Udaya Kiran Marelli; Blake Mertz; Johannes G Beck; Florian Opperer; Florian Rechenmacher; Horst Kessler; Victor J Hruby
Journal:  Biochemistry       Date:  2017-08-01       Impact factor: 3.162

7.  Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.

Authors:  Alexander V Mayorov; Minying Cai; Kevin B Chandler; Ravil R Petrov; April R Van Scoy; Zerui Yu; Dustin K Tanaka; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

Review 8.  The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases.

Authors:  Minying Cai; Victor J Hruby
Journal:  Curr Protein Pept Sci       Date:  2016       Impact factor: 3.272

Review 9.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

Review 10.  Female sexual dysfunction: potential for pharmacotherapy.

Authors:  Jean L Fourcroy
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.